drinking while on semaglutide and Alcohol: Can It Reduce Cravings? GLP-1 drugs like Ozempic may

Orforglipron is the first small molecule GLP-1 to complete a Phase III trial, lowering A1C by an average of 1.3% to 1.6% across doses

This potential surge in popularity for products promoting physical and mental health could inspire a positive outlook on the potential benefits of GLP-1RA

doi: 10.1016/j.ebiom.2020.102917

This is not just academic detail

The FDA and pharmaceutical manufacturers establish strict appearance specifications for injectable medications precisely because visual inspection is an accessible, immediate safety measure

The user base is simultaneously growing in absolute terms (new adopters coming in as costs fall and access expands) and cycling at high rates (a majority discontinuing within 12 months)